References
[1] W. E. Anthony et al., “Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults,” Cell Rep., vol. 39, no. 2, p. 110649, Apr. 2022, doi: 10.1016/j.celrep.2022.110649.
[2] A. Palleja et al., “Recovery of gut microbiota of healthy adults following antibiotic exposure,” Nat. Microbiol., vol. 3, no. 11, pp. 1255–1265, Nov. 2018, doi: 10.1038/s41564-018-0257-9.
[3] J. de Gunzburg et al., “Protection of the Human Gut Microbiome From Antibiotics,” J. Infect. Dis., vol. 217, no. 4, pp. 628–636, Jan. 2018, doi: 10.1093/infdis/jix604.
[4] M. Reyman et al., “Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial,” Nat. Commun., vol. 13, no. 1, p. 893, Feb. 2022, doi: 10.1038/s41467-022-28525-z.
[5] O. Manor et al., “Health and disease markers correlate with gut microbiome composition across thousands of people,” Nat. Commun., vol. 11, no. 1, p. 5206, Oct. 2020, doi: 10.1038/s41467-020-18871-1.
[6] A. J. Gasparrini et al., “Persistent metagenomic signatures of early-life hospitalization and antibiotic treatment in the infant gut microbiota and resistome,” Nat. Microbiol., vol. 4, no. 12, pp. 2285–2297, Dec. 2019, doi: 10.1038/s41564-019-0550-2.
[7] V. Stevens, G. Dumyati, L. S. Fine, S. G. Fisher, and E. van Wijngaarden, “Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 53, no. 1, pp. 42–48, Jul. 2011, doi: 10.1093/cid/cir301.
[8] K. A. Brown, N. Khanafer, N. Daneman, and D. N. Fisman, “Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection,” Antimicrob. Agents Chemother., vol. 57, no. 5, pp. 2326–2332, May 2013, doi: 10.1128/AAC.02176-12.
[9] CDC, “Most cases of C. diff occur while taking antibiotics or soon after.,” Centers for Disease Control and Prevention, Jul. 12, 2021. https://www.cdc.gov/cdiff/index.html (accessed Jan. 20, 2022).
[10] Q. Guo, J. Z. Goldenberg, C. Humphrey, R. El Dib, and B. C. Johnston, “Probiotics for the prevention of pediatric antibiotic-associated diarrhea,” Cochrane Database Syst. Rev., vol. 4, p. CD004827, Apr. 2019, doi: 10.1002/14651858.CD004827.pub5.
[11] H. Szajewska and M. Kołodziej, “Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults,” Aliment. Pharmacol. Ther., vol. 42, no. 10, pp. 1149–1157, Nov. 2015, doi: 10.1111/apt.13404.
[12] C. P. Selinger, A. Bell, A. Cairns, M. Lockett, S. Sebastian, and N. Haslam, “Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial,” J. Hosp. Infect., vol. 84, no. 2, pp. 159–165, Jun. 2013, doi: 10.1016/j.jhin.2013.02.019.
[13] J. H. Song and Y. S. Kim, “Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention,” Gut Liver, vol. 13, no. 1, pp. 16–24, Jan. 2019, doi: 10.5009/gnl18071.
[14] Z. Aversa et al., “Association of Infant Antibiotic Exposure With Childhood Health Outcomes,” Mayo Clin. Proc., vol. 96, no. 1, Art. no. 1, Jan. 2021, doi: 10.1016/j.mayocp.2020.07.019.
[15] D. H. Kim, K. Han, and S. W. Kim, “Effects of Antibiotics on the Development of Asthma and Other Allergic Diseases in Children and Adolescents,” Allergy Asthma Immunol. Res., vol. 10, no. 5, Art. no. 5, Sep. 2018, doi: 10.4168/aair.2018.10.5.457.
[16] S. E. Zven, A. Susi, E. Mitre, and C. M. Nylund, “Association Between Use of Multiple Classes of Antibiotic in Infancy and Allergic Disease in Childhood,” JAMA Pediatr., vol. 174, no. 2, Art. no. 2, Feb. 2020, doi: 10.1001/jamapediatrics.2019.4794.
[17] D. M. Patrick et al., “Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies,” Lancet Respir. Med., vol. 8, no. 11, pp. 1094–1105, Nov. 2020, doi: 10.1016/S2213-2600(20)30052-7.